Related Experiment Video
Updated: May 28, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Update on antithrombotic agents in secondary stroke prevention
Tatjana Rundek1, Vanja Basić-Kes, Sandra Morović
1Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA.
Acta Clinica Croatica
|November 1, 2011
Summary
Stroke recurrence poses a significant threat to survivors, impacting healthcare costs. Antithrombotic therapy is crucial for secondary stroke prevention and improving patient outcomes.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Public Health
Background:
- Recurrent stroke is a leading cause of death and disability in stroke survivors.
- Improving survival rates after a first ischemic stroke increases the burden of stroke recurrence.
- Stroke recurrence remains a primary concern despite advancements in prevention and treatment.
Purpose of the Study:
- To review the role of antithrombotic therapy in secondary stroke prevention.
- To highlight the clinical impact of antithrombotic strategies on reducing stroke recurrence.
Main Methods:
- Literature review focusing on antithrombotic treatments for secondary stroke prevention.
- Analysis of clinical practice guidelines and research on stroke recurrence.
Main Results:
- Antithrombotic therapy significantly reduces the risk of recurrent stroke.
- Specific antithrombotic agents demonstrate varying efficacy in different patient populations.
- Optimizing antithrombotic strategies is key to improving secondary prevention.
Conclusions:
- Antithrombotic therapy is a cornerstone of secondary stroke prevention.
- Effective management of antithrombotic treatment can mitigate the morbidity and mortality associated with recurrent strokes.
- Further research may refine antithrombotic approaches for personalized stroke prevention.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...